Article info
PDFInflammatory bowel disease
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
- Correspondence to:
Dr William J Sandborn
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.william{at}mayo.edu
Citation
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Publication history
- Accepted January 29, 2007
- Revised January 25, 2007
- First published February 13, 2007.
Online issue publication
April 18, 2016
Article Versions
- Previous version (18 April 2016).
- You are viewing the most recent version of this article.
William Sandborn, Paul Rutgeerts, Douglas Wolf, and Remo Panaccione have served as consultants for Abbott Laboratories. William Sandborn, Stephen Hanauer, Paul Rutgeerts, and Remo Panaccione have participated in continuing medical education events supported by unrestricted educational grants from Abbott Laboratories. Jeffrey Kent, Barry Bittle, Ju Li, and Paul Pollack are Abbott employees.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2007 by Gut